Therapeutic Response

ER positive, ESR1 oncogenic variants, and HER2-negative status confers therapeutic sensitivity to Imlunestrant in patients with Invasive Breast Carcinoma.

Statements

Source and description
Inluriyo (imlunestrant) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to imlunestrant for the treatment of adult patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.